Vascular Biogenics Ltd. (VBLT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$0.00

P/E Ratio

N/A

Market Cap

$10.63K

Jan 30, 2024Mar 8, 2024Apr 10, 2024May 20, 2024Jun 21, 2024Jul 24, 2024Aug 27, 2024Oct 2, 2024Nov 4, 2024Dec 5, 2024Jan 20, 2025$0.00$10.00
  • PVT
Description

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Metrics

Overview

  • HQModi’in, JM
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerVBLT
  • Price$0.0011+10.00%

Trading Information

  • Market cap$0.01M
  • Float53.65%
  • Average Daily Volume (1m)30,510
  • Average Daily Volume (3m)109,742
  • EPS-$14.58

Company

  • Revenue$0.66M
  • Rev growth (1yr)N/A
  • Net income-$5.22M
  • Gross margin-3,100.00%
  • EBITDA margin-265,800.00%
  • EBITDA-$5.32M
  • EV$3.65M
  • EV/Revenue5.54
  • P/EN/A
  • P/SN/A
  • P/B0.00
Documents